Completed OBSERVATIONAL NCT04790838

Pooled Analysis FP_SX_250_50

Pooled Analysis of Individual Subjects' Data After Combining the Data From the Bioequivalence Studies Conducted for Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals (Test, T) vs ADVAIR DISKUS® 250/50 mcg Inhalation Powder/GSK (Reference, R)

Sponsor: Becro Ltd.

Conditions Asthma

Interventions Reference Test

Updated 3 times since 2021 Last updated: Mar 5, 2021 Started: Jun 2, 2019 Primary completion: Dec 31, 2020 Completion: Dec 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Asthma and is currently completed. Becro Ltd. leads this study, which shows 3 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Apr 2021 — Jul 2024 [monthly]

Completed

First recorded

Jun 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Becro Ltd.
Respirent Pharmaceuticals Co Ltd.

Data source: Respirent Pharmaceuticals Co Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Larissa, Greece